Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Bilateral Wrist Septic Arthritis Caused by Group B β-Hemolytic Streptococcus: A Case Report.

Cureus·2026
Same author

Sex-Based Disparities in Health Care Access and Utilization Among Patients With Atrial Fibrillation.

JAMA network open·2026
Same author

PR Interval Alternans and the Mystery of Inverse Decremental Conduction.

JACC. Case reports·2026
Same author

When QTc Shrinks After Rhythm Conversion.

JACC. Case reports·2026
Same author

Patient health or corporate profits-Shouldn't the former come first?

The American journal of medicine·2026
Same author

Brain Abscess Arising From Pansinusitis in an Immunocompetent Young Adult: A Diagnostic Challenge.

Cureus·2026

Video Experimental Relacionado

Updated: Jun 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

El Dronedarone es el Dronedarone.

Chinmay Patel1, Gan-Xin Yan, Peter R Kowey

  • 1Main Line Health Heart Center and Lankenau Hospital, Wynnewood, PA 19096, USA.

Circulation
|August 19, 2009
PubMed
Resumen
Este resumen es generado por máquina.

La dronedarona, un derivado de la amiodarona, mantiene eficazmente el ritmo sinusal en pacientes con fibrilación auricular. Si bien reduce la mortalidad, su perfil de seguridad requiere una cuidadosa consideración, especialmente en casos graves de insuficiencia cardíaca.

Más Videos Relacionados

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Videos de Experimentos Relacionados

Last Updated: Jun 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Área de la Ciencia:

  • Cardiología Cardiología.
  • Farmacología Farmacología.

Sus antecedentes:

  • La amiodarona es eficaz para la fibrilación auricular, pero tiene efectos secundarios significativos.
  • La dronedarona, un derivado de amiodarona no yodado, se desarrolló para mitigar estos problemas.
  • Ambos fármacos se dirigen a corrientes de iones múltiples y poseen propiedades antiadrenérgicas.

Objetivo del estudio:

  • Revisar la seguridad y eficacia de la dronedarona en el tratamiento de la fibrilación auricular.
  • Para comparar el perfil de la dronedarona con la amiodarona, centrándose en los efectos extra-cardiacos.

Principales métodos:

  • Revisión de los datos de ensayos clínicos con dronedarona en la fibrilación auricular.
  • Análisis de las propiedades farmacocinéticas y farmacodinámicas.
  • Evaluación de los puntos finales de seguridad y eficacia.

Principales resultados:

  • Dronedarone demostró eficacia en el mantenimiento del ritmo sinusal y el control de la frecuencia ventricular.
  • Se demostró que reduce la mortalidad y la morbilidad en pacientes con fibrilación auricular de alto riesgo.
  • Existen preocupaciones con respecto a su seguridad en pacientes con insuficiencia cardíaca grave.

Conclusiones:

  • La dronedarona ofrece una opción terapéutica para la fibrilación auricular, equilibrando la eficacia con un perfil de efectos secundarios potencialmente mejorado en comparación con la amiodarona.
  • La selección cuidadosa del paciente es crucial, especialmente evitar el uso en insuficiencia cardíaca grave.
  • Investigaciones adicionales pueden aclarar la seguridad a largo plazo y las poblaciones óptimas de pacientes.